La Piel Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 23-12-2024
- Paid Up Capital ₹ 0.10 M
as on 23-12-2024
- Company Age 10 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 20.91%
(FY 2022)
- Profit 184.92%
(FY 2022)
- Ebitda 313.81%
(FY 2022)
- Net Worth 11.51%
(FY 2022)
- Total Assets 8.94%
(FY 2022)
About La Piel Biotech
The Company is engaged in the Fmcg Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Seema Chaudhary, Vibha Sharma, and Belaben Patel serve as directors at the Company.
- CIN/LLPIN
U24231GJ2014PTC078788
- Company No.
078788
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Feb 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does La Piel Biotech Private Limited offer?
La Piel Biotech Private Limited offers a wide range of products and services, including Cosmetics, Hair & Beauty Products, Skin Creams, Pharmaceutical Medicine, Body Lotions, Moisturizing Lotion, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Hair Shampoo, Ketoconazole Shampoo, Face Wash.
Who are the key members and board of directors at La Piel Biotech?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Seema Chaudhary  | Director | 18-Feb-2014 | Current |
| Vibha Sharma | Additional Director | 30-Apr-2014 | Current |
| Belaben Patel | Director | 29-Jun-2014 | Current |
Financial Performance of La Piel Biotech.
La Piel Biotech Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 20.91% increase. The company also saw a substantial improvement in profitability, with a 184.92% increase in profit. The company's net worth Soared by an impressive increase of 11.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of La Piel Biotech?
In 2021, La Piel Biotech had a promoter holding of 40.00% and a public holding of 60.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at La Piel Biotech?
Unlock and access historical data on people associated with La Piel Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of La Piel Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped La Piel Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
